CORTCorcept TherapeuticsCORT info
$41.94info5.60%24h
Global rank3091
Market cap$4.32B
Change 7d21.97%
YTD Performance89.67%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Corcept Therapeutics (CORT) Stock Overview

    Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

    CORT Stock Information

    Symbol
    CORT
    Address
    149 Commonwealth DriveMenlo Park, CA 94025United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.corcept.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 327 3270

    Corcept Therapeutics (CORT) Price Chart

    -
    Value:-

    Corcept Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $41.94
    N/A
    Market Cap
    $4.32B
    N/A
    Shares Outstanding
    103.08M
    N/A
    Employees
    299.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org